β-Catenin Directly Sequesters Adipocytic and Insulin Sensitizing Activities but Not Osteoblastic Activity of PPARγ2 in Marrow Mesenchymal Stem Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Rahman, Sima ^a   Czernik, Piotr J ^a   Lu, Yalin ^a   Lecka Czernik, Beata ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR; LITHIUM CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROTEIN KINASE B; ROSIGLITAZONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; WNT10B PROTEIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; INSULIN SIGNALING; MARKER GENE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ADIPOCYTES; ANILIDES; ANIMALS; BETA CATENIN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION; GENE SILENCING; INSULIN; LITHIUM CHLORIDE; MESENCHYMAL STROMAL CELLS; MICE; MUTATION; OSTEOBLASTS; PPAR GAMMA; PROTEIN STABILITY; PROTEOLYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84871264726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051746     Document Type: Article

References (49)

1. Lian JB, Stein GS, Javed A, van Wijnen AJ, Stein JL, et al. (2006) Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 7: 1-16.
2. Tontonoz P, Spiegelman BM, (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
3. Heikkinen S, Auwerx J, Argmann CA, (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 1771: 999-1013.
4. Lecka-Czernik B, Gubrij I, Moerman EA, Kajkenova O, Lipschitz DA, et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 74: 357-371.
5. Rhee EJ, Oh KW, Yun EJ, Jung CH, Park CY, et al. (2007) The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene with serum osteoprotegerin levels in healthy Korean women. Exp Mol Med 39: 696-704.
6. Costa V, Gallo MA, Letizia F, Aprile M, Casamassimi A, et al. (2010) PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues. PPAR Res 2010.
7. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS, (2002) PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16: 27-32.
8. Bruedigam C, Koedam M, Chiba H, Eijken M, van Leeuwen JP, (2008) Evidence for multiple peroxisome proliferator-activated receptor gamma transcripts in bone: fine-tuning by hormonal regulation and mRNA stability. FEBS Lett 582: 1618-1624.
9. Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, et al. (2010) A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells 28: 916-927.
10. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B, (2004) Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3: 379-389.
11. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148: 2669-2680.
12. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846-855.
13. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, et al. (2004) Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 5: 1007-1012.
14. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, et al. (2009) PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106: 232-246.
15. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, et al. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376-2384.
16. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B, (2006) Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38: 74-85.
17. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, et al. (2011) Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481.
18. Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, et al. (2008) Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med 14: 188-193.
19. Hinds TD Jr, Stechschulte LA, Cash HA, Whisler D, Banerjee A, et al. (2011) Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid and PPAR{gamma} receptors. J Biol Chem 286: 42911-42922.
20. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, et al. (2011) Lrp5 functions in bone to regulate bone mass. Nat Med 17: 684-691.
21. Logan CY, Nusse R, (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810.
22. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, et al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521.
23. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
24. Glass DA, 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764.
25. Day TF, Guo X, Garrett-Beal L, Yang Y, (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8: 739-750.
26. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, et al. (2007) Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22: 1924-1932.
27. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, et al. (2003) High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18: 960-974.
28. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, et al. (2005) Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280: 21162-21168.
29. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, et al. (2010) Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30: 3071-3085.
30. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C, (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8: 727-738.
31. Angers S, Moon RT, (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468-477.
32. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC, (2005) Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 26: 898-915.
33. Liu J, Wang H, Zuo Y, Farmer SR, (2006) Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 26: 5827-5837.
34. Liu J, Farmer SR, (2004) Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027.
35. Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, et al. (2012) Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 50: 477-489.
36. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, et al. (2010) Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 25: 2138-2147.
37. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, et al. (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9: 1273-1285.
38. Takada I, Kouzmenko AP, Kato S, (2009) Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5: 442-447.
39. Mizushima S, Nagata S, (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322.
40. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, et al. (1993) Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Nat Acad Sci USA 90: 5723-5727.
41. Kennell JA, MacDougald OA, (2005) Wnt signaling inhibits adipogenesis through beta-catenin-dependent and-independent mechanisms. J Biol Chem 280: 24004-24010.
42. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41: 6640-6650.
43. Ono M, Inkson CA, Kilts TM, Young MF, (2011) WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J Bone Miner Res 26: 193-208.
44. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ, (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492: 1-18.
45. Aslanidi G, Kroutov V, Philipsberg G, Lamb K, Campbell-Thompson M, (2007) Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats. Am J Physiol Endocrinol Metab 293: E726-736.
46. Vertino AM, Taylor-Jones JM, Longo KA, Bearden ED, Lane TF, et al. (2005) Wnt10b deficiency promotes coexpression of myogenic and adipogenic programs in myoblasts. Mol Biol Cell 16: 2039-2048.
47. Sen B, Xie Z, Case N, Ma M, Rubin C, et al. (2008) Mechanical strain inhibits adipogenesis in mesenchymal stem cells by stimulating a durable beta-catenin signal. Endocrinology 149: 6065-6075.
48. Case N, Thomas J, Sen B, Styner M, Xie Z, et al. (2011) Mechanical Regulation of Glycogen Synthase Kinase 3beta (GSK3beta) in Mesenchymal Stem Cells Is Dependent on Akt Protein Serine 473 Phosphorylation via mTORC2 Protein. J Biol Chem 286: 39450-39456.
49. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.